Advertisement
Advertisement
OCGN
Ocugen, Inc. Common Stock
1.47
USDSponsored
0.00
0.00%
May 13, 15:46 UTC -4
Closed
Pre-Market
1.50
+0.03
+2.38%
OCGN Earnings Reports
Positive Surprise Ratio
OCGN beat 19 of 40 last estimates.
48%
Next Report
Date of Next Report
Jul 30, 2026
Estimate for Q2 26 (Revenue/ EPS)
$849.96K
/-$0.05
Implied change from Q1 26 (Revenue/ EPS)
-44.56%
/-16.67%
Implied change from Q2 25 (Revenue/ EPS)
-38.10%
/--
Ocugen, Inc. Common Stock earnings per share and revenue
On May 05, 2026, OCGN reported earnings of -0.06 USD per share (EPS) for Q1 26, missing the estimate of -0.05 USD, resulting in a -14.29% surprise. Revenue reached 1.53 million, compared to an expected 550.80 thousand, with a 178.32% difference. The market reacted with a -19.46% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of -0.05 USD, with revenue projected to reach 849.96 thousand USD, implying an decrease of -16.67% EPS, and decrease of -44.56% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kamada Ltd
Report Date
May 13, 2026 For Q1 26
Estimate
$0.11
Actual
$0.07
Surprise
-40.32%
Abeona Therapeutics Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+17.31%
Milestone Pharmaceuticals Inc. Common Shares
Report Date
May 13, 2026 For Q1 26
Estimate
$0.31
Actual
-$0.20
Surprise
-163.94%
Spero Therapeutics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Equillium, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.04
Actual
-$0.06
Surprise
-34.53%
Spruce Biosciences, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$8.99
Actual
-$8.94
Surprise
+0.58%
BeyondSpring Inc. Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-Actual
-$0.05
Surprise
-
Tango Therapeutics, Inc.
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.32
Surprise
-0.13%
Longeveron Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.19
Surprise
-12.89%
Bionano Genomics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.96
Actual
-$0.76
Surprise
+21.57%
FAQ
What were Ocugen, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Ocugen, Inc. Common Stock reported EPS of -$0.06, missing estimates by -14.29%, and revenue of $1.53M, 178.32% above expectations.
How did the market react to Ocugen, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -19.46%, changed from $1.85 before the earnings release to $1.49 the day after.
When is Ocugen, Inc. Common Stock expected to report next?
The next earning report is scheduled for Jul 30, 2026.
What are the forecasts for Ocugen, Inc. Common Stock's next earnings report?
Based on 6
analysts, Ocugen, Inc. Common Stock is expected to report EPS of -$0.05 and revenue of $849.96K for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement